Cargando...
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patien...
Guardado en:
| Publicado en: | Ther Adv Med Oncol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535754/ https://ncbi.nlm.nih.gov/pubmed/31205507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919849753 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|